PMID- 26810066
OWN - NLM
STAT- MEDLINE
DCOM- 20170301
LR  - 20181202
IS  - 1423-0380 (Electronic)
IS  - 1010-4283 (Linking)
VI  - 37
IP  - 7
DP  - 2016 Jul
TI  - Prognostic impact and potential interaction of EGFR and c-Met in the progression 
      of esophageal squamous cell carcinoma.
PG  - 9771-9
LID - 10.1007/s13277-015-4692-4 [doi]
AB  - This study is to examine EGFR and c-Met variation in precancerous lesion, early 
      esophageal squamous cell carcinoma (ESCC), and advanced ESCC and to explore their 
      prognostic significance. EGFR and c-Met were detected by immunohistochemistry 
      (IHC) and fluorescence in situ hybridization (FISH). Of 158 endoscopy resection 
      (ER) specimens, c-Met high expression and FISH positive were 44.9 and 12.6 %, 
      respectively. EGFR high expression and FISH positive were 2.5 and 19.6 %, 
      respectively. Of 84 surgical specimens, c-Met high expression and FISH positive 
      were 50 and 8.3 %, respectively. EGFR high expression and FISH positive were 7.1 
      and 28.5 %, respectively. A significant correlation was observed between c-Met 
      and EGFR FISH positive both in ER (P < 0.001) and surgical specimens (P = 0.029). 
      Patients with EGFR high expression had poorer disease-free survival (DFS) and 
      overall survival (OS) (P = 0.031 and P = 0.013) in c-Met high-expression group 
      but not in c-Met low-expression group (P = 0.301 and P = 0.439). C-Met FISH 
      positive did not represent a statistically significant adverse prognosis until 
      24 months later (P = 0.027 and 0.048). EGFR and c-Met might be involved in the 
      tumorigenesis and development of ESCC. EGFR high expression has different 
      prognostic significance in patients with differing c-Met expression status. C-Met 
      FISH positive represent delayed prognostic factor.
FAU - Wang, Haixing
AU  - Wang H
AD  - Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, 
      People's Republic of China.
FAU - Jiang, Dongxian
AU  - Jiang D
AD  - Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, 
      People's Republic of China.
FAU - Song, Qi
AU  - Song Q
AD  - Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, 
      People's Republic of China.
FAU - Xu, Chen
AU  - Xu C
AD  - Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, 
      People's Republic of China.
FAU - Shi, Yuan
AU  - Shi Y
AD  - Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, 
      People's Republic of China.
FAU - Li, Xiaojing
AU  - Li X
AD  - Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, 
      People's Republic of China.
FAU - Huang, Jie
AU  - Huang J
AD  - Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, 
      People's Republic of China.
FAU - Xu, Yifan
AU  - Xu Y
AD  - Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, 
      People's Republic of China.
FAU - Sujie, Akesu
AU  - Sujie A
AD  - Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, 
      People's Republic of China.
FAU - Zeng, Haiying
AU  - Zeng H
AD  - Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, 
      People's Republic of China.
FAU - Zhong, Yunshi
AU  - Zhong Y
AD  - Endoscopic Center, Zhongshan Hospital, Fudan University, Shanghai, 200032, 
      People's Republic of China.
FAU - Tan, Lijie
AU  - Tan L
AD  - Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, 
      200032, People's Republic of China. tan.lijie@zs-hospital.sh.cn.
FAU - Hou, Yingyong
AU  - Hou Y
AD  - Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, 
      People's Republic of China. houyingyong@hotmail.com.
LA  - eng
PT  - Journal Article
DEP - 20160125
PL  - Netherlands
TA  - Tumour Biol
JT  - Tumour biology : the journal of the International Society for Oncodevelopmental 
      Biology and Medicine
JID - 8409922
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.10.1 (MET protein, human)
RN  - EC 2.7.10.1 (Proto-Oncogene Proteins c-met)
SB  - IM
MH  - Biomarkers, Tumor/genetics/*metabolism
MH  - Carcinoma, Squamous Cell/genetics/metabolism/*pathology
MH  - Disease Progression
MH  - ErbB Receptors/genetics/*metabolism
MH  - Esophageal Neoplasms/genetics/metabolism/*pathology
MH  - Female
MH  - Follow-Up Studies
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - In Situ Hybridization
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Invasiveness
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Proto-Oncogene Proteins c-met/genetics/*metabolism
MH  - Retrospective Studies
MH  - Survival Rate
OTO - NOTNLM
OT  - EGFR and c-Met
OT  - Early and advanced ESCC
OT  - Potential interaction
OT  - Precancerous lesion
OT  - Prognosis
EDAT- 2016/01/27 06:00
MHDA- 2017/03/03 06:00
CRDT- 2016/01/27 06:00
PHST- 2015/10/17 00:00 [received]
PHST- 2015/12/16 00:00 [accepted]
PHST- 2016/01/27 06:00 [entrez]
PHST- 2016/01/27 06:00 [pubmed]
PHST- 2017/03/03 06:00 [medline]
AID - 10.1007/s13277-015-4692-4 [pii]
AID - 10.1007/s13277-015-4692-4 [doi]
PST - ppublish
SO  - Tumour Biol. 2016 Jul;37(7):9771-9. doi: 10.1007/s13277-015-4692-4. Epub 2016 Jan 
      25.